 Home > Active Ingredient News > Drugs Articles > Zhongsheng Pharmaceuticals intends to contribute US$515 million to Cosing Zhongwei for the development of the new crown vaccine

Zhongsheng Pharmaceuticals intends to contribute US$515 million to Cosing Zhongwei for the development of the new crown vaccine

 Last Update: 2020-12-19
 Source: Internet
 Author: User

Tags

research study articles

ltd group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 7, China Biopharmaceuticals announced that Hong Kong Jung-kong Co., Ltd., a wholly-owned subsidiary, had entered into an agreement to invest US$515 million in the further development, capacity expansion and production of the new crown inactivated vaccine, as well as other development and operation activities of Kexing Zhongwei.
the completion of this capital investment, China Biopharmaceuticals will have a 15.03 percent interest in the registered capital of Coxing Zhongwei.
Cosing Zhongwei will be recorded in the company's financial statements as an associated company.
same day, Kexing Holding Biotechnology Co., Ltd. announced on its official website that its subsidiary Beijing Kexing Zhongwei Biotechnology Co., Ltd. in the research of the new crown inactivated vaccine Kelleford ™ underage group I./II. clinical research has been launched.
June 14 this year, Koxing announced that the new crown vaccine I./II. phase clinical study (0,14 procedures) revealed blind, preliminary results show that the vaccine has good safety and immunogenicity.
the new crown inactivated vaccine has also appeared at the China International Trade Fair in Services.
mid-October, Zhejiang launched an emergency vaccination of the new crown vaccine, using the vaccine from Koxing.
phase III clinical studies are being conducted in Brazil, Indonesia, Turkey, Chile and other countries.
。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Reta 5mg 10mg 15mg Vial Weight Loss Anti-diabetes Fat Loss

CAS No.: 2381089-83-2

Pharmacy Grade

$110-130/UNIT FOB

Best price Pure Tirzepatide powder 10mg vial Tirzepatide CAS 2023788-19-2 ouda

CAS No.: 2023788-19-2

Pharmacy Grade

$40.00/G FOB

Hot Sale 1-Adamantanamine Hydrochloride /1-Adamantanamine HCl CAS 665-66-7

CAS No.: 665-66-7

Pharmacy Grade

$20-25/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.